Most Recent Articles by Mark A. Socinski, MD
Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Although prevalence of cytogenetic abnormality in tumor biopsy is low, finding one or more abnormalities can expand the patient's treatment options.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|